Low-Dose Ketamine: A New Approach to Treating Depression & Anxiety

A growing number of clinicians are reporting success using low-dose sublingual ketamine (LDSL) as an at-home treatment for depression and other mood disorders, challenging conventional approaches that often rely on higher doses administered in clinical settings. The treatment, which can cost as little as $15 to $60 per month, is gaining attention for its accessibility, lower risk profile and potential for sustained improvement, according to Dr. Mitchell Liester, who has been observing positive patient responses for three years.

Ketamine’s antidepressant effects have been known for some time, with the FDA approving intranasally-administered esketamine for treatment-resistant depression in 2019 and for major depressive disorder with acute suicidal ideation in 2020, as reported by the National Institute of Mental Health.

The traditional understanding of how ketamine works centers on its ability to block NMDA receptors in the brain. This blockage increases levels of brain-derived neurotrophic factor (BDNF), often referred to as “Miracle-Grow for the brain,” which promotes neuroplasticity – the formation of new connections between brain cells. However, Dr. Liester emphasizes that ketamine’s impact extends beyond this mechanism.

“You can think of neuroplasticity as your brain’s ability to rewire itself,” Dr. Liester explained. “Depression, anxiety, and trauma are disorders of brain connectivity—neural networks become rigid or break down. Ketamine ‘repairs’ these networks.” He argues that the neuroplastic changes needed for lasting improvement don’t necessarily require high doses, and that repeated low-dose administration may offer cumulative benefits.

Further research indicates that ketamine also interacts with sigma-1 receptors, proteins involved in the cellular stress response. Activation of these receptors protects neurons from damage, reduces inflammation, and aids in cellular repair, potentially explaining ketamine’s benefits in conditions beyond depression, such as chronic pain and neurodegenerative disorders.

LDSL ketamine offers practical advantages over intravenous (IV) ketamine infusions. IV ketamine requires medical supervision, can necessitate time off work, and often requires transportation assistance due to its effects. LDSL ketamine, taken at home, avoids these logistical hurdles and associated costs. The lower doses minimize the risk of dissociative experiences, which some patients find distressing or re-traumatizing.

Concerns about abuse potential are also reduced with LDSL ketamine. While high doses of ketamine can be reinforcing and lead to addiction, the lower doses used in this treatment generally do not produce euphoria or a “high.” Dr. Liester has even observed that some patients report a decreased desire for other addictive substances after starting LDSL ketamine. However, he stresses the importance of ongoing monitoring to prevent excessive use.

The potential for adverse effects associated with chronic, high-dose ketamine use, such as bladder problems, and cognitive impairment, are also minimized with the lower-dose approach. In fact, many of Dr. Liester’s patients report improvements in memory, learning, and problem-solving skills.

While research on LDSL ketamine is still emerging, initial results are promising. Dr. Liester notes that doses as low as 5mg per day have produced antidepressant effects comparable to or exceeding those achieved with IV infusions. He also reports that LDSL ketamine appears effective not only for depression and bipolar disorder, but also for anxiety disorders, post-traumatic stress disorder, ADHD, and borderline personality disorder.

Despite its potential benefits, LDSL ketamine is not without risks and requires medical supervision. Even at low doses, it can interact with other medications and may affect blood pressure and heart rate. Patients with certain cardiac conditions, uncontrolled hypertension, psychotic disorders, or active substance use disorders may not be suitable candidates, and it should not be used during pregnancy or breastfeeding.

Dr. Liester emphasizes the importance of working with a clinician familiar with both high-dose and low-dose ketamine approaches to determine the optimal treatment plan for each individual. He suggests that the discovery of LDSL ketamine challenges the “bigger-is-better” bias often found in medicine, suggesting that lower doses may be sufficient – and even preferable – for many patients.